Journal of Clinical Endocrinology & Metabolism, Vol 80, 1922-1928, Copyright © 1995 by Endocrine Society

ARTICLES

Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency

S Fujimoto, T Kubo, H Tanaka, M Miura and Y Seino
Department of Pediatrics, Okayama University Medical School, Japan.

To assess the bone growth status in healthy children, urinary pyridinoline (PYR) and deoxypyridinoline (DPYR) levels, which are specific bone resorption markers, were studied in 192 healthy children, aged 3-14 yr. In healthy children ages 3-5 yr, the urinary PYR level was about 10 times higher than that in healthy adults (238.3 +/- 22.7 pmol/mumol Cr in boys and 261.8 +/- 14.2 pmol/mumol Cr in girls; mean +/- SE, and the level declined gradually with age. In boys, the urinary PYR level began to rise at about 10 yr of age and peaked 2 yr later, declining thereafter. In girls, urinary PYR level declined rapidly after 11 yr. The age-related changes in urinary DPYR levels closely resembled those in urinary PYR levels. We further studied PYR and DPYR levels in 17 GH-deficient children who were beginning treatment with GH. After 2-3 months of GH therapy, 1.3-fold significant increases in urinary PYR and DPYR levels were observed. These results indicate that the bone resorption in children is increased relative to that in adults, that urinary PYR and DPYR levels are increased during puberty when the growth rate is markedly elevated, and that bone resorption in children is accelerated by GH therapy.

This article has been cited by other articles:

				M. Rauchenzauner, A. Schmid, P. Heinz-Erian, K. Kapelari, G. Falkensammer, A. Griesmacher, G. Finkenstedt, and W. Hogler Sex- and Age-Specific Reference Curves for Serum Markers of Bone Turnover in Healthy Children from 2 Months to 18 Years J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 443 - 449. [Abstract] [Full Text] [PDF]

				B. Westhoff, R. Krauspe, A. E. Kalke, D. Hermsen, B. Kowall, R. Willers, and U. Schneider Urinary excretion of deoxypyridinoline in Perthes' disease: A PROSPECTIVE, CONTROLLED COMPARATIVE STUDY IN 83 CHILDREN J Bone Joint Surg Br, July 1, 2006; 88-B(7): 967 - 971. [Abstract] [Full Text] [PDF]

				C Land, W F Blum, A Stabrey, and E Schoenau Seasonality of growth response to GH therapy in prepubertal children with idiopathic growth hormone deficiency Eur. J. Endocrinol., May 1, 2005; 152(5): 727 - 733. [Abstract] [Full Text] [PDF]

				R. Eastell Role of oestrogen in the regulation of bone turnover at the menarche J. Endocrinol., May 1, 2005; 185(2): 223 - 234. [Abstract] [Full Text] [PDF]

				K. Zhu, X. Du, C. T Cowell, H. Greenfield, B. Blades, T. A Dobbins, Q. Zhang, and D. R Fraser Effects of school milk intervention on cortical bone accretion and indicators relevant to bone metabolism in Chinese girls aged 10-12 y in Beijing Am. J. Clinical Nutrition, May 1, 2005; 81(5): 1168 - 1175. [Abstract] [Full Text] [PDF]

				R. Schweizer, D. D. Martin, C. P. Schwarze, G. Binder, A. Georgiadou, J. Ihle, and M. B. Ranke Cortical Bone Density Is Normal in Prepubertal Children with Growth Hormone (GH) Deficiency, but Initially Decreases during GH Replacement due to Early Bone Remodeling J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5266 - 5272. [Abstract] [Full Text] [PDF]

				K. Tanimoto, M. Imada, S. Ohno, A. Sasaki, K. Honda, and K. Tanne Association between Craniofacial Growth and Urinary Bone Metabolic Markers (Pyridinoline, Deoxypyridinoline) in Growing Rats J. Dent. Res., January 1, 2003; 82(1): 28 - 32. [Abstract] [Full Text] [PDF]

				H. W. Vesper, L. M. Demers, R. Eastell, P. Garnero, M. Kleerekoper, S. P. Robins, A. K. Srivastava, G. R. Warnick, N. B. Watts, and G. L. Myers Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline Clin. Chem., February 1, 2002; 48(2): 220 - 235. [Abstract] [Full Text] [PDF]

				F. Rauch, M. Georg, A. Stabrey, C. Neu, W. F. Blum, T. Remer, F. Manz, and E. Schoenau Collagen Markers Deoxypyridinoline and Hydroxylysine Glycosides: Pediatric Reference Data and Use for Growth Prediction in Growth Hormone-deficient Children Clin. Chem., February 1, 2002; 48(2): 315 - 322. [Abstract] [Full Text] [PDF]

				W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet Optimizing GH Therapy in Adults and Children Endocr. Rev., August 1, 2001; 22(4): 425 - 450. [Abstract] [Full Text] [PDF]

				S. M Husain, Z. Mughal, G. Williams, K. Ward, C. S Smith, J. Dutton, and W. D Fraser Urinary excretion of pyridinium crosslinks in healthy 4-10 year olds Arch. Dis. Child., April 1, 1999; 80(4): 370 - 373. [Abstract] [Full Text]

				F. GAROFALO, A. PIGA, R. LALA, S. CHIABOTTO, M. DI STEFANO, and G. C. ISAIA Bone Metabolism in Thalassemia Ann. N.Y. Acad. Sci., June 30, 1998; 850(1): 475 - 478. [Full Text] [PDF]

				M. Zanze, J. C. Souberbielle, C. Kindermans, C. Rossignol, and M. Garabedian Procollagen Propeptide and Pyridinium Cross-Links as Markers of Type I Collagen Turnover: Sex- and Age-Related Changes in Healthy Children J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2971 - 2977. [Abstract] [Full Text] [PDF]